Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Lipum

14,65 SEK

-0,34 %

Mindre end 1K følgere

LIPUM

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-0,34 %
+47,09 %
+3,90 %
+1,03 %
+22,08 %
+3,90 %
+3,51 %
-
-33,01 %

Lipum is a biopharmaceutical company. The company is in the clinical phase and specializes in the discovery and development of new treatments for chronic inflammatory diseases. The company's drug candidate is based on an antibody intended to be used in treatments to block a specific molecule in the immune system. The drug candidate is in the clinical phase with preclinical data for rheumatism. The company is also evaluating other inflammatory diseases. Lipum has its operations in Umeå.

Læs mere
Markedsværdi
310,76 mio. SEK
Aktieomsætning
93,86 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
29.12
2025

Ekstraordinær generalforsamling '26

25.2
2026

Årsrapport '25

28.4
2026

Delårsrapport Q1'26

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Eksterne analyser28.11.2025, 10.33

Lipum: Merging with Flerie - VH Corp

* Flerie has proposed a merger with Lipum * Topline data support BSSL’s role in RA * Our model suggests a fair value of SEK 16.29 per share A key issue in Lipum’s preparations for the anticipated phase II study has been the financing. This will now likely...

Lipum
Pressemeddelelse28.11.2025, 09.03

Västra Hamnen Market Focus: Lipum: Merging with Flerie

Lipum
Pressemeddelelse27.11.2025, 13.08

Redeye: Lipum (Q3 review) - Going private

Lipum

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse27.11.2025, 11.19

BioStock: Lipum steps up ahead of phase II – clear signals in Q3

Lipum
Selskabsmeddelelse27.11.2025, 07.00

Lipum AB – interim report Q3 for the period July-September 2025

Lipum
Pressemeddelelse20.11.2025, 10.38

BioStock: Lipum’s CEO on the merger with Flerie and the path toward phase II

Lipum
Selskabsmeddelelse18.11.2025, 07.02

STATEMENT BY THE BOARD OF DIRECTORS OF LIPUM IN VIEW OF THE MERGER OFFER BY FLERIE

Lipum
Selskabsmeddelelse18.11.2025, 07.00

Flerie and Lipum have agreed on a merger plan

Lipum
Pressemeddelelse30.10.2025, 07.30

Lipum presents new topline data supporting BSSL’s role in rheumatoid arthritis

Lipum
Pressemeddelelse7.10.2025, 07.07

BioStock: Lipum gears up with new CFO – one month into the assignment

Lipum
Pressemeddelelse25.9.2025, 09.48

BioStock: Video from Lipum’s live interview at BioStock Investing in Life Science – From Seed to Success

Lipum
Eksterne analyser1.9.2025, 11.01

Lipum: Finding financial support - VH Corp

* Preparations progress as planned * Loan facilities provide support for 2025 * Our model suggests a fair value of SEK 16.29 per share Lipum reported in its Q2 report that the manufacturing process of SOL-116 is nearing the final phase. The drug candidate...

Lipum
Pressemeddelelse1.9.2025, 11.00

Västra Hamnen Market Focus: Lipum: Finding financial support

Lipum
Pressemeddelelse29.8.2025, 07.55

BioStock: Focus on preparation for Lipum during Q2

Lipum
Pressemeddelelse28.8.2025, 15.08

Redeye: Lipum Q2 - Focus on securing funding

Lipum
Selskabsmeddelelse28.8.2025, 06.17

Lipum AB – interim report Q2 for the period January-June 2025

Lipum
Pressemeddelelse7.8.2025, 06.30

Lipum Welcomes Tobias Helgesson as New Chief Financial Officer

Lipum
Selskabsmeddelelse1.8.2025, 13.00

Lipum AB (publ) has decided to postpone the interim report Q2 2025 to August 28, 2025

Lipum
Pressemeddelelse8.7.2025, 06.30

Lipum Announces Outcome of Warrant Programs TO A 2025/2028 and TO B 2025/2028

Lipum
Pressemeddelelse27.6.2025, 12.58

BioStock: Professor regarding the collaboration with Lipum: “Our aim is to personalise RA treatment”

Lipum
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.